Showing: 11 - 20 of 24 RESULTS

Global Anti-aging Treatment Market to Surpass US$ 34.49 Billion by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global anti-aging treatment market is estimated to be valued at US$ 21.06 billion in 2020 and is expected to exhibit a CAGR of 7.3% over the forecast period (2020-2027).

Key Trends and Analysis of the Global Anti-aging Treatment Market:

Key trends in the market include increasing launches of anti-aging treatment products, increasing number of aesthetic procedures, and increasing acquisitions, partnerships, and agreements by key players. These are expected to aid in growth of the market.

According to the 2018 Plastic Surgery Statistics Report by the American Society of Plastic Surgeons, approximately 17.7 million cosmetic procedures were performed in the U.S. in 2018. According to the same source, the top three minimally invasive cosmetic procedures include botulinum toxin type A, soft tissue fillers, and chemical peel.

Moreover, key players are focusing on raising finances through investments by private equity platform in order to enhance their market presence, which is expected to drive growth of the anti-aging treatment market over the forecast period. For instance, in May 2018, Rodan + Fields, LLC, a U.S.-based skincare brand, announced that TPG Capital, an American investment company, invested in Rodan + Fields, LLC. The investment through TPG Capital will provide Rodan + Fields, LLC with an access to better business building expertise in order to expand its business domestically and internationally.

Furthermore, increasing product launches by key players is expected to propel the market growth over the forecast period. For instance, in January 2019, T.A. Sciences, a provider of clinically tested wellness products, launched T.A.-65, an anti-oxidant formula, developed for reducing the visible signs of aging, evening out discolored and blotchy skin tones, increasing skin firmness and tone, and diminishing facial wrinkles and folds.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4210

Key Market Takeaways:

The global anti-aging treatment market is expected to exhibit a CAGR of 7.3% over the forecast period. This is owing to increasing number of aesthetic procedures. According to the International Society of Aesthetic Plastic Surgery, around 227,089 facial rejuvenation procedures were performed in Japan in 2017.

Among regions, North America is expected to hold dominant position in the global market over the forecast period, owing to high presence of key players such as NuFACE and Alma Laser, and rising number of minimally invasive cosmetic procedures. According to the International Society of Aesthetic Plastic Surgery, around 1,903,660 non-surgical procedures including botulinum toxin, were performed in the U.S. in 2017.

Key players operating in the global anti-aging treatment market include Allergan Plc, Estée Lauder Companies, Shiseido Company, Beiersdorf AG, L’Oréal S.A, NuFACE, Ostium Cosmetics, PhotoMedex, Inc, Alma Laser, Rodan & Fields, LLC, and others

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4210

Market Segmentation:

  • Global Anti-aging Treatment Market, By Product Type:

  • Global Anti-aging Treatment Market, By Technology:

  • Global Anti-aging Treatment Market, By End User:

    • Hospitals

    • Skin Care Clinics

    • Homecare Settings

    • Others

  • Global Anti-aging Treatment Market, By Region:

    • North America

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Rest of Latin America

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

      • Russia

      • Rest

Live Covid-19 Global Updates – The New York Times

Credit…Anna Moneymaker for The New York Times

In photos and videos released by the White House, there was hardly any sign that President Trump is sick, and painting in the broadest of strokes, his doctors offered a fairly rosy portrait of his condition.

But to some outside experts who examined that portrait closely, some things seemed off.

How much, for example, should people make of the president’s fluctuating oxygen levels? And why did his doctors decide to begin treatment with a steroid drug?

Too some infectious disease experts, there were signs that Mr. Trump may be suffering a more severe case of Covid-19, the disease caused by the coronavirus, than his physicians have acknowledged.

“This is no longer aspirationally positive,” Dr. Esther Choo, a professor of emergency medicine at Oregon Health & Science University in Portland, said of the doctors’ statements. “And it’s much more than just an ‘abundance of caution’ kind of thing.”

Based his doctors’ account, Mr. Trump’s symptoms appear to have rapidly progressed since he announced early Friday that he had tested positive for the coronavirus.

Mr. Trump had a “high fever” on Friday, and there were two occasions when his blood oxygen levels dropped, his doctors said, including to a level that can indicate that a patient’s lungs are compromised. The symptom is seen in many patients with severe Covid-19.

The president’s medical team also said that he had been prescribed dexamethasone. The drug is a steroid used to head off an immune system overreaction that kills many Covid-19 patients. And it is generally reserved for those with severe illness.

“The dexamethasone is the most mystifying of the drugs we’re seeing him being given at this point,” said Dr. Thomas McGinn, physician in chief at Northwell Health, the largest health care provider in New York State.

The drug, he said, is normally not used unless the patient’s condition seems to be deteriorating.

“Suddenly, they’re throwing the kitchen sink at him,” Dr. McGinn said. “It raises the question: Is he sicker than we’re hearing, or are they being overly aggressive because he is the president, in a way that could be potentially harmful?”

Of course, given the patient, there may be another explanation.

Some experts raised an additional possibility: that the president is directing his own care, and demanding intense treatment despite risks he may not fully understand. The pattern even has a name: V.I.P. syndrome.

Credit…Alex Wroblewski/Reuters

As President Trump and some of his associates test positive for the coronavirus, the number of new cases reported each day across the United States has been slowly rising.

The country is at a key moment in the pandemic, and spread of the virus could worsen significantly through the autumn, experts fear, as colder weather forces people indoors. Every day, some 43,000 new cases

Global Precision Medicine Market 2020-2030: Focus on Ecosystem, Technology, Application, and Competitive Landscape

The “Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape – Analysis and Forecast, 2020-2030” report has been added to ResearchAndMarkets.com’s offering.

Global Precision Medicine Market to Reach $278.61 Billion by 2030

Precision medicine refers to the medicine developed as per an individual’s genetic profile. It provides guidance regarding the prevention, diagnosis, and treatment of diseases. The segmentation of the population is done depending on the genome structure of the individuals and their compatibility with a specific drug molecule.

In the precision medicine market, the application of molecular biology is to study the cause of a patient’s disease at the molecular level, so that target-based therapies or individualized therapies can be applied to cure the patient’s health-related problems.

This industry is gaining traction due to the increasing awareness about healthcare among individuals, integration of smart devices such as smartphones and tablets into healthcare, and increasing collaborations and agreements of IT firms with the diagnostics and biopharmaceutical companies for the development of precision diagnostic tools.

Within the research report, the market is segmented on the basis of product type, ecosystem application, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide 360-degree coverage of the domain.

Key Topics Covered:

1 Product Definition

2 Research Scope

3 Research Methodology

4 Global Precision Medicine Market Overview

4.1 Market Definition

4.2 Precision Medicine: A Frontier in the Genesis of Patient-centric Medicine

4.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy

4.4 Initiatives and Programs

4.5 Precision Medicine: Enabling Technologies and Applications

4.5.1 Innovators

4.5.1.1 3D DNA Printing

4.5.1.1.1 Introduction

4.5.1.1.2 Role of 3D DNA Printing

4.5.1.2 RNA-Seq

4.5.1.2.1 Introduction

4.5.1.2.2 Role of RNA-Seq in Precision Medicine

4.5.1.2.3 Key Players

4.5.1.3 4D Molecular Imaging

4.5.1.3.1 Introduction

4.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine

4.5.1.3.3 Key Players

4.5.2 Early Adopters

4.5.2.1 CRISPR

4.5.2.1.1 Introduction

4.5.2.1.2 Role of CRISPR in Precision Medicine

4.5.2.1.3 Key Players

4.5.2.2 Blockchain

4.5.2.3 Imaging Informatics

4.5.3 Early Majority

4.5.3.1 Artificial Intelligence (AI)

4.5.3.2 Circulating Free DNA (cfDNA)

4.5.3.3 Big Data

4.5.3.4 Next-Generation Sequencing (NGS)

4.5.3.5 Health Informatics

4.5.3.6 Bioinformatics

4.5.4 Late Majority

4.5.4.1 Polymerase Chain Reactions (PCR)

4.5.4.2 Microarray

4.6 COVID-19 Impact on the Global Precision Medicine Market

5 Market Dynamics

5.1 Overview

5.2 Market Drivers

5.2.1 Advancement of Sequencing Technologies

5.2.2 Rising Prevalence of Chronic Diseases

5.2.3 Growing Demand for Preventive Care

5.2.4 Shifting the Significance in Medicine, from Reaction to Prevention

5.2.5 Reducing Adverse Drug Reactions Through Pharmacogenomics Test

5.2.6 Potential to Reduce the Overall Healthcare Cost Across the Globe

5.3 Market Restraints

5.3.1 Unified Framework for Data Integration

5.3.2 Limited Knowledge about Molecular Mechanism/ Interaction

5.3.3 Lack of Robust Reimbursement Landscape

5.3.4 Regulatory Hurdles

5.4 Market Opportunities

5.4.1 Targeted Gene Therapy

5.4.2 Expansion into the Emerging Markets

5.4.3 Collaboration and Partnerships Across Value Chain to Accelerate the Market Entry

6 Industry Insights

Global virtual fitness expands during pandemic, expected to reach $44.7B by 2026: report

Virtual fitness is having a moment, according to a new report.

A recent analysis by market research firm Report Ocean has found that the online fitness market is expected to reach $44.7 billion globally by 2026, compared to $6 billion globally last year.

Before the coronavirus, online workouts were already gaining in popularity as a way to accommodate busy lifestyles among a growing number of “fitness-conscious people,” a press release about the report said.

However, even more people turned to online fitness classes when brick-and-mortar gyms were forced to temporarily close during the pandemic.

AMAZON DENIES WORKING WITH ECHELON ON ‘PRIME BIKE,’ ECHELON CEO CALLS IT ‘MISCOMMUNICATION’

According to the report, it is likely that even after life gets back to normal, people will stick with virtual workouts because “they offer flexibility of time and place.”

The online fitness market is expected to continue to grow after the pandemic because of the flexibility and accessibility of virtual workouts, according to a recent analysis by Report Ocean. (iStock)

NEW YORK SPORTS CLUB OWNER SEALS POTENTIAL LENDER TAKEOVER DEAL

According to Report Ocean, on-demand streaming classes made up a majority of the global online fitness market last year and is expected to stay that way, because those classes “offer access to a variety of workout classes at clients’ suitability.”

However, live streaming is also becoming more popular “among regular fitness enthusiasts” and people who want “reliable” workouts, the report said.

FLYWHEEL, SOULCYCLE COMPETITOR, FILES FOR BANKRUPTCY

Report Ocean also found that subscription models for virtual fitness classes saw the highest growth compared to advertisement and hybrid-based revenue models.

“The client acceptance is primarily driven by its cost efficiency similar to signing up with a coach in-person,” the press release said.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

In order for the global online fitness market to continue to grow, the report said, programs should be progressive and adopt various “fitness strategies” and should help older adults, as well. The market is expected to continue to grow because online fitness has become popular among elderly people, who get “more personalized attention,” the report said.

“Elderly individuals are increasingly focusing on a healthier lifestyle, and they follow advice from qualified fitness specialists,” the report said.

“The adoption of virtual fitness is gaining momentum among this age group as they hire personal virtual trainers for the correct implementation of fitness training procedures,” it added.

CLICK HERE TO READ MORE ON FOX BUSINESS

Source Article

Global Brain Health Supplements Market to Surpass US$ 13,492.6 Million by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global brain health supplements market is estimated to be valued at US$ 7,038.0 million in 2020 and is expected to exhibit a CAGR of 8.5% during the forecast period (2020-2027).

Key Trends and Analysis:

Key trends in the market include rising incidence of depression, anxiety and stress levels, increasing health awareness, and product launches.

Rising incidence of Alzheimer, depression, anxiety, stress, and other mental health conditions is expected to contribute to the growth of the brain health supplements market. For instance, according to data published by Alzheimer’s Association in 2017, around 5.5 million people in the U.S. of all ages were suffering from Alzheimer’s dementia.

Moreover, key players operating in the market are focused on product launches in order to expand their offerings. For instance, in June 2020, Elysium Health, in partnership with University of Oxford, U.K., announced the launch of Matter – a brain health supplement which is based on the Oxford’s VITACOG study which contains vitamin B, omega 3 lysine complex and bilberry extract for cognitive health and memory loss treatment.

Market players are investing in validating efficiency of novel products in the market. Moreover, market players are committed to offering new and improved products to address the critical unmet need for brain health supplements. For instance, in May 2020, a study conducted by researchers from Central Queensland University in collaboration with the Deakin University in Australia and Nanyang Technological University in Singapore showed positive results for USANA CopaPrime, a product of USANA Health Sciences, Inc.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4205

Key Market Takeaways:

The global brain health supplements market is expected to exhibit a CAGR of 8.5% during the forecast period, owing to increasing product launches. For instance, in April 2015, Cerebral Success, a brain-health company announced the launch of SmartX, a combination of Cognizin Citicoline with other brain health supplements to enhance and improve mental energy and focus. The company has made its products available through distribution channels such as GNC stores, Amazon.com and eSupplements.com, luckyvitamin.com.

North America is expected to hold a dominant position in the global brain health supplements market during the forecast period owing to increasing health awareness, high expenditure on supplements and adoption of inorganic growth strategies by market players. For instance, in January 2015, Synergy Strips Corp announced the acquisition of FOCUSfactor a brain health supplement brand, an asset from the Factor Nutrition Labs, LLC. The FOCUSfactor is sold at retail stores such as Costco, Sam’s Club, Walmart, Walgreens, CVS and The Vitamin Shoppe.

Competitive Landscape:

Key players operating in the global brain health supplements market are AlternaScript, LLC, Accelerated Intelligence Inc., Liquid Health, Inc., HVMN Inc., Natural Factors Nutritional Products Ltd., KeyView Labs, Inc., Onnit Labs, LLC, Purelife Bioscience Co., Ltd., Quincy Bioscience, Cerebral Success, Amway, Puori, Ocean Health, and Schiff.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4205

Market Segmentation:

  • Global Brain Health Supplements Market, By Product Type:

    • Herbal Extracts

      • Ginseng

      • Ginkgo Biloba

      • Curcumin

      • Lions Mane

      • Others

    • Vitamins & Minerals

BIAL Goes Global With New US Research Center and Acquisition of Promising Parkinson’s Disease Programs

  • BIAL Biotech to be based in Cambridge, Massachusetts and will be a Research Center of Excellence dedicated to genetically-defined Parkinson’s disease

  • LTI-291 clinical program and other research programs in Parkinson’s disease acquired from Lysosomal Therapeutics, Inc.

  • R&D team led by Peter Lansbury, professor of neurology at Harvard Medical School

  • Investment may add up to 130 million dollars depending on the accomplishment of downstream development, and several regulatory and commercial milestones

BIAL, a pharmaceutical company based in Portugal with locations across Europe and dedicated to R&D in CNS diseases, announced today that it has established a new affiliate in the United States of America, BIAL Biotech Investments Inc. (BIAL Biotech). This new research center focused on genetically-defined Parkinson’s disease is based in Cambridge, Massachusetts, a prominent biotech hub in the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005323/en/

Simultaneously, BIAL announced that it has acquired worldwide rights of LTI-291 and all the Parkinson’s disease research programs of Lysosomal Therapeutics Inc. (LTI) and taken on the entire R&D team.

António Portela, executive president of BIAL, reveals: “Our entry into the US with the creation of BIAL Biotech and the acquisition of the promising programs from LTI, is a decisive step towards the fulfilment of our mission to contribute to improving the quality of life of people worldwide. The development of this new research center in the US, is a landmark of enormous relevance for us. We are investing in science and research, through our direct presence in one of the most important research hubs in the world and in one of the most promising areas of medicine.

This acquisition not only provides the company with a pipeline of new product candidates in Parkinson’s disease but also an experienced R&D team, led by Peter Lansbury, professor of neurology at Harvard Medical School and a recognized thought leader in the field of neurodegenerative diseases.

With this acquisition, BIAL is expanding its pipeline, namely with the integration of new compounds in neurodegeneration already in clinical development, specifically for Parkinson’s disease, where the pharmaceutical company already has a significant market position.

The executive president of BIAL also points out: “The compounds we’ve acquired are based on genetics, a new field of research for us. The lead asset, which now has the code name ‘BIA 28-6156/LTI-291’, has an innovative mechanism of action and presents the potential of being a first disease-modifying therapy for a genetic subset of Parkinson’s disease. It has successfully completed a Phase I trial program and should be ready to start Phase II studies in 2021. We´re progressing from symptomatic treatment to an intervention in the mechanisms of the disease, which is very exciting for BIAL.

“We are happy to be part of BIAL and take the lead on the growth story in the US,” says Kees Been, former CEO of LTI and now CEO of BIAL Biotech. “With the commitment and resources of BIAL we will be able to accelerate our novel

Global Antifungal Drugs Market to Surpass US$ 13,132.8 Mn by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global antifungal drugs market is estimated to be valued at US$ 11,591.0 Mn in 2020 and is expected to exhibit a CAGR of 1.8% during the forecast period (2020-2027).

Key Trends and Analysis of the Global Antifungal Drugs Market:

The increasing incidence of invasive candidiasis and vaginal candidiasis is expected to propel the global antifungal drugs market growth. The rising prevalence of invasive candidiasis, vaginal candidiasis, and preterm births poses high economic burden on the patient-population. For instance, according to the Centers for Disease Control and Prevention (CDC), candidemia, a form of invasive candidiasis, was one of the most common bloodstream infections in the U.S., with an average incidence of around 9 per 100,000 cases between 2013 and 2017.

Moreover, according to the same source, in 2017, around 84% of the total healthcare cost and 48% of the hospitalizations for candida infections was attributable to invasive candidiasis. The average cost per hospitalization for invasive candidiasis was around US$ 64,723 to US$ 153,090.

The increasing number of preterm births is expected to boost the market growth. For instance, according to the Kolling Institute of Medical Research published its result in 2015, that shows vaginal candidiasis can increase the risk of preterm births.

Moreover, according to a survey by researchers from the University of Miyazaki in 2017, the incidence of vulvovaginal candidiasis (VC) during pregnancy is 13 to 20% globally.

Furthermore, according to the Obstetric and Gynecology Department, Italy, 2018, VC is estimated to be the second most common cause of vaginitis and is found in 40% of women with vaginal discomfort. VC can cause systemic infections in premature neonates, particularly those with low birth weight.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/237

Key Market Takeaways:

The global antifungal drugs market is expected to exhibit a CAGR of 1.8% during the forecast period (2020-2027), owing to the increasing incidence of invasive candidiasis and vaginal candidiasis.

The growth of the North America antifungal drugs market is attributed to launches of antifungal drugs in the U.S.

Competitive Landscape:

Key players operating in the global antifungal drugs market are GlaxoSmithKline Plc, Bayer AG, Abbott Laboratories, Merck & Co., Inc, Glenmark Pharmaceuticals Limited, Enzon Pharmaceuticals, Inc., Pfizer Inc., Gilead Sciences, Inc., Sanofi S.A. and Astellas Pharma, Inc.

Buy-Now this Research report @ https://www.coherentmarketinsights.com/insight/buy-now/237

 

Market Segmentation:

  • Global Antifungal Drugs Market, By Dosage Form:

    • Powders

    • Ointments

    • Drugs

    • Others

  • Global Antifungal Drugs Market, By Region:

    • North America

    • Europe

      • U.K.

      • Germany

      • Italy

      • Spain

      • France

      • Russia

      • Rest of Europe

    • Asia Pacific

      • Australia

      • India

      • China

      • Japan

      • ASEAN

      • South Korea

      • Rest of Asia Pacific

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Rest of Latin America

    • Middle East

      • GCC

      • Israel

      • Rest of Middle East

    • Africa

      • South Africa

      • Central Africa

      • North Africa

Related Market Intelligence Report:

Brain Health Supplements Market, by Product Type (Herbal Extracts {Ginseng, Ginkgo Biloba, Curcumin, Lions Mane, and Others}, Vitamins & Minerals {Vitamin B, Vitamin C &  E, and Others}, and Natural Molecules {Acetyl-L-Carnitine, Alpha GPC, Citicoline, Docosahexaenoic Acid, and Others}), by Application (Memory

U.N. chief: time for national plans to help fund global COVID-19 vaccine effort

NEW YORK/GENEVA (Reuters) – United Nations Secretary-General Antonio Guterres said on Wednesday it is time for countries to start using money from their national COVID-19 recovery and response plans to help fund the World Health Organization’s global vaccine plan.

The Access to COVID-19 Tools (ACT) Accelerator programme and its COVAX facility has so far received $3 billion, but needs another $35 billion. It aims to deliver two billion doses of coronavirus vaccines by the end of next year, 245 million treatments and 500 million tests.

“The ACT-Accelerator provides the only safe and certain way to re-open the global economy as quickly as possible. A national vaccine effort in a handful of countries will not unlock the doors to the global economy and restore livelihoods,” Guterres told a high-level virtual U.N. event.

Britain’s Foreign Secretary Dominic Raab – a co-host of the meeting along with Guterres, the World Health Organization (WHO) and South Africa – urged other countries to join the global effort, saying the ACT-Accelerator is the best hope of bringing the pandemic under control.

WHO chief Tedros Adhanom Ghebreyesus said 167 countries have joined COVAX global vaccines facility, representing 70% of the world’s population, adding: “And the list is growing every day”. He said one million people are confirmed to have lost their lives to COVID-19, but “the real number is certainly higher.”

Guterres said the programme needed an immediate injection of $15 billion to “avoid losing the window of opportunity” for advance purchase and production, to build stocks in parallel with licensing, boost research, and help countries prepare.

“We cannot allow a lag in access to further widen already vast inequalities,” Guterres told the virtual event.

“But let’s be clear: We will not get there with donors simply allocating resources only from the Official Development Assistance budget,” he said. “We need to think bigger. It is time for countries to draw funding from their own response and recovery programmes.”

Guterres called on all countries to step up significantly in the next three months.

He noted that developed countries had spent trillions of dollars on the socio-economic impacts of the crisis so “surely, we can invest a small fraction of that to stop the spread of the disease everywhere.”

Bill Gates told the U.N. event that the Bill & Melinda Gates Foundation had signed an agreement with 16 pharmaceutical companies on Wednesday.

“In this agreement the companies commit to, among other things, scaling up manufacturing, at an unprecedented speed, and making sure that approved vaccines reach broad distribution as early as possible,” Gates said.

Reporting by Michelle Nichols and Stephanie Ulmer-Nebehay; Editing by Chizu Nomiyama and Paul Simao

Source Article

time for national plans to help fund global COVID-19 vaccine effort

By Michelle Nichols and Stephanie Nebehay

NEW YORK/GENEVA (Reuters) – United Nations Secretary-General Antonio Guterres said on Wednesday it is time for countries to start using money from their national COVID-19 recovery and response plans to help fund the World Health Organization’s global vaccine plan.

The Access to COVID-19 Tools (ACT) Accelerator programme and its COVAX facility has so far received $3 billion, but needs another $35 billion. It aims to deliver two billion doses of coronavirus vaccines by the end of next year, 245 million treatments and 500 million tests.

“The ACT-Accelerator provides the only safe and certain way to re-open the global economy as quickly as possible. A national vaccine effort in a handful of countries will not unlock the doors to the global economy and restore livelihoods,” Guterres told a high-level virtual U.N. event.

Britain’s Foreign Secretary Dominic Raab – a co-host of the meeting along with Guterres, the World Health Organization (WHO) and South Africa – urged other countries to join the global effort, saying the ACT-Accelerator is the best hope of bringing the pandemic under control.

WHO chief Tedros Adhanom Ghebreyesus said 167 countries have joined COVAX global vaccines facility, representing 70% of the world’s population, adding: “And the list is growing every day”. He said one million people are confirmed to have lost their lives to COVID-19, but “the real number is certainly higher.”

Guterres said the programme needed an immediate injection of $15 billion to “avoid losing the window of opportunity” for advance purchase and production, to build stocks in parallel with licensing, boost research, and help countries prepare.

“We cannot allow a lag in access to further widen already vast inequalities,” Guterres told the virtual event.

“But let’s be clear: We will not get there with donors simply allocating resources only from the Official Development Assistance budget,” he said. “We need to think bigger. It is time for countries to draw funding from their own response and recovery programmes.”

Guterres called on all countries to step up significantly in the next three months.

He noted that developed countries had spent trillions of dollars on the socio-economic impacts of the crisis so “surely, we can invest a small fraction of that to stop the spread of the disease everywhere.”

Bill Gates told the U.N. event that the Bill & Melinda Gates Foundation had signed an agreement with 16 pharmaceutical companies on Wednesday.

“In this agreement the companies commit to, among other things, scaling up manufacturing, at an unprecedented speed, and making sure that approved vaccines reach broad distribution as early as possible,” Gates said.

(Reporting by Michelle Nichols and Stephanie Ulmer-Nebehay; Editing by Chizu Nomiyama and Paul Simao)

Source Article

Global Precision Medicine Market 2020-2030: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy

The MarketWatch News Department was not involved in the creation of this content.

Dublin, Sep 30, 2020 (GLOBE NEWSWIRE via COMTEX) —
Dublin, Sept. 30, 2020 (GLOBE NEWSWIRE) — The “Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape – Analysis and Forecast, 2020-2030” report has been added to ResearchAndMarkets.com’s offering.

Global Precision Medicine Market to Reach $278.61 Billion by 2030

Precision medicine refers to the medicine developed as per an individual’s genetic profile. It provides guidance regarding the prevention, diagnosis, and treatment of diseases. The segmentation of the population is done depending on the genome structure of the individuals and their compatibility with a specific drug molecule.

In the precision medicine market, the application of molecular biology is to study the cause of a patient’s disease at the molecular level, so that target-based therapies or individualized therapies can be applied to cure the patient’s health-related problems.

This industry is gaining traction due to the increasing awareness about healthcare among individuals, integration of smart devices such as smartphones and tablets into healthcare, and increasing collaborations and agreements of IT firms with the diagnostics and biopharmaceutical companies for the development of precision diagnostic tools.

Within the research report, the market is segmented on the basis of product type, ecosystem application, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide 360-degree coverage of the domain.

Key Topics Covered:

1 Product Definition

2 Research Scope

3 Research Methodology

4 Global Precision Medicine Market Overview
4.1 Market Definition
4.2 Precision Medicine: A Frontier in the Genesis of Patient-centric Medicine
4.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
4.4 Initiatives and Programs
4.5 Precision Medicine: Enabling Technologies and Applications
4.5.1 Innovators
4.5.1.1 3D DNA Printing
4.5.1.1.1 Introduction
4.5.1.1.2 Role of 3D DNA Printing
4.5.1.2 RNA-Seq
4.5.1.2.1 Introduction
4.5.1.2.2 Role of RNA-Seq in Precision Medicine
4.5.1.2.3 Key Players
4.5.1.3 4D Molecular Imaging
4.5.1.3.1 Introduction
4.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine
4.5.1.3.3 Key Players
4.5.2 Early Adopters
4.5.2.1 CRISPR
4.5.2.1.1 Introduction
4.5.2.1.2 Role of CRISPR in Precision Medicine
4.5.2.1.3 Key Players
4.5.2.2 Blockchain
4.5.2.3 Imaging Informatics
4.5.3 Early Majority
4.5.3.1 Artificial Intelligence (AI)
4.5.3.2 Circulating Free DNA (cfDNA)
4.5.3.3 Big Data
4.5.3.4 Next-Generation Sequencing (NGS)
4.5.3.5 Health Informatics
4.5.3.6 Bioinformatics
4.5.4 Late Majority
4.5.4.1 Polymerase Chain Reactions (PCR)
4.5.4.2 Microarray
4.6 COVID-19 Impact on the Global Precision Medicine Market

5 Market Dynamics
5.1 Overview
5.2 Market Drivers
5.2.1 Advancement of Sequencing Technologies
5.2.2 Rising Prevalence of Chronic Diseases
5.2.3 Growing Demand for Preventive Care
5.2.4 Shifting the Significance in Medicine, from Reaction to Prevention
5.2.5 Reducing Adverse Drug Reactions Through Pharmacogenomics Test
5.2.6 Potential to Reduce the Overall Healthcare Cost Across the Globe
5.3 Market Restraints
5.3.1 Unified Framework for Data Integration
5.3.2 Limited Knowledge about Molecular Mechanism/ Interaction
5.3.3 Lack of Robust Reimbursement Landscape
5.3.4 Regulatory